• -
  • English
  • Japanese
  • Korean
表紙
市場調查報告書
商品編碼
1063700

RNAi治療藥的全球市場:產業分析，趨勢，市場規模，2027年前的預測

RNAi Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027
出版日期: | 出版商: Infinium Global Research (IGR) | 英文 100 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球RNAi治療藥的市場規模在預測期間內預計將以9％的年複合成長率增長。

這份報告提供全球RNAi治療藥市場調查，提供市場預測和概要，市場的推動因素與阻礙因素的分析，COVID-19影響，各類型，各用途，各給藥途徑，各終端用戶，各地區的市場分析，競爭情形，主要企業的簡介等系統性資訊。

目錄

第1章 序文

  • 報告的說明
  • 調查方法
  • 研究途徑

第2章 摘要整理

  • 市場概況
  • 市場預測
  • 市場地區的亮點

第3章 全球RNAi治療藥市場:概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • COVID-19對市場的影響分析
  • 波特的五力分析
  • IGR-成長矩陣分析
    • 各類型
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各地區
  • 市場價值鏈分析

第4章 RNAi治療藥市場:宏觀指標分析

第5章 全球RNAi治療藥市場:各類型

  • 低分子干涉RNA(siRNA)
  • 微型核糖核酸(miRNA)

第6章 全球RNAi治療藥市場:各用途

  • 遺傳性疾病
  • 腫瘤
  • 神經退化性疾病
  • 感染疾病
  • 腎臟疾病
  • 其他

第7章 全球RNAi治療藥市場:各給藥途徑

  • 皮內注射
  • 肺通知
  • 靜脈注射

第8章 全球RNAi治療藥市場:各終端用戶

  • 診斷研究所
  • 調查及學術研究所
  • 醫院

第9章 全球RNAi治療藥市場(2021年∼2027年):各地區

  • 北美
    • 各類型
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各國
  • 歐洲
    • 各類型
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各國
  • 亞太地區
    • 各類型
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各國
  • 其他地區
    • 各類型
    • 各用途
    • 各給藥途徑
    • 各終端用戶
    • 各子地區

第10章 企業簡介和競爭情形

  • 競爭情形
  • 企業簡介
    • Alnylam Pharmaceuticals, Inc.
    • Sanofi
    • Olix Pharmaceuticals, Inc.
    • Arbutus Biopharma Corporation
    • Silence Therapeutics
    • Rexahn Pharmaceuticals, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • Quark
    • Others
目錄
Product Code: HC08734

The report on the global RNAi therapeutics market provides qualitative and quantitative analysis for the period from 2019 to 2027. The report predicts the global RNAi therapeutics market to grow with a CAGR of 9% over the forecast period from 2021-2027. The study on RNAi therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2019 to 2027.

The report on RNAi therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global RNAi therapeutics market over the period of 2019 to 2027. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global RNAi therapeutics market over the period of 2019 to 2027. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • Collaborations between drug distribution companies and contract research organizations (CROs)
  • The rising deaths of people by cancer
  • Advancing in drug delivery technology which can treat rare and chronic diseases

2) Restraints

  • High investment

3) Opportunities

  • Public institutions are focusing on R&D work on nanotechnology

Research Methodology

A) Primary Research

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include

  • 1. Key Opinion Leaders associated with Infinium Global Research
  • 2. Internal and External subject matter experts
  • 3. Professionals and participants from the industry

Our primary research respondents typically include

  • 1. Executives working with leading companies in the market under review
  • 2. Product/brand/marketing managers
  • 3. CXO level executives
  • 4. Regional/zonal/ country managers
  • 5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

  • 1. Company reports and publications
  • 2. Government/institutional publications
  • 3. Trade and associations journals
  • 4. Databases such as WTO, OECD, World Bank, and among others.
  • 5. Websites and publications by research agencies

Segment Covered

The global RNAi therapeutics market is segmented on the basis of type, application, route of administration, and end user.

The Global RNAi Therapeutics Market by Type

  • Small Interfering RNAs (siRNA)
  • MicroRNA (miRNA)

The Global RNAi Therapeutics Market by Application

  • Genetic Disorders
  • Oncology
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Renal Diseases
  • Others

The Global RNAi Therapeutics Market by Route of Administration

  • Intradermal Injections
  • Pulmonary Delivery
  • Intravenous Injections

The Global RNAi Therapeutics Market by End User

  • Diagnostic Laboratories
  • Research and Academic Laboratories
  • Hospitals

Company Profiles

The companies covered in the report include

  • Alnylam Pharmaceuticals, Inc.
  • Sanofi
  • Olix Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Silence Therapeutics
  • Rexahn Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Quark
  • Others

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the RNAi therapeutics market.

2. Complete coverage of all the segments in the RNAi therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2027.

3. Comprehensive analysis of the companies operating in the global RNAi therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methods
  • 1.3. Research Approaches

2. Executive Summary

  • 2.1. RNAi Therapeutics Market Highlights
  • 2.2. RNAi Therapeutics Market Projection
  • 2.3. RNAi Therapeutics Market Regional Highlights

3. Global RNAi Therapeutics Market Overview

  • 3.1. Introduction
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
  • 3.3. Analysis of COVID-19 impact on the RNAi Therapeutics Market
  • 3.4. Porter's Five Forces Analysis
  • 3.5. IGR-Growth Matrix Analysis
    • 3.5.1. IGR-Growth Matrix Analysis by Type
    • 3.5.2. IGR-Growth Matrix Analysis by Application
    • 3.5.3. IGR-Growth Matrix Analysis by Route of Administration
    • 3.5.4. IGR-Growth Matrix Analysis by End User
    • 3.5.5. IGR-Growth Matrix Analysis by Region
  • 3.6. Value Chain Analysis of RNAi Therapeutics Market

4. RNAi Therapeutics Market Macro Indicator Analysis

5. Global RNAi Therapeutics Market by Type

  • 5.1. Small Interfering RNAs (siRNA)
  • 5.2. MicroRNA (miRNA)

6. Global RNAi Therapeutics Market by Application

  • 6.1. Genetic Disorders
  • 6.2. Oncology
  • 6.3. Neurodegenerative Disorders
  • 6.4. Infectious Diseases
  • 6.5. Renal Diseases
  • 6.6. Others

7. Global RNAi Therapeutics Market by Route of Administration

  • 7.1. Intradermal Injections
  • 7.2. Pulmonary Delivery
  • 7.3. Intravenous Injections

8. Global RNAi Therapeutics Market by End User

  • 8.1. Diagnostic Laboratories
  • 8.2. Research and Academic Laboratories
  • 8.3. Hospitals

9. Global RNAi Therapeutics Market by Region 2021-2027

  • 9.1. North America
    • 9.1.1. North America RNAi Therapeutics Market by Type
    • 9.1.2. North America RNAi Therapeutics Market by Application
    • 9.1.3. North America RNAi Therapeutics Market by Route of Administration
    • 9.1.4. North America RNAi Therapeutics Market by End User
    • 9.1.5. North America RNAi Therapeutics Market by Country
  • 9.2. Europe
    • 9.2.1. Europe RNAi Therapeutics Market by Type
    • 9.2.2. Europe RNAi Therapeutics Market by Application
    • 9.2.3. Europe RNAi Therapeutics Market by Route of Administration
    • 9.2.4. Europe RNAi Therapeutics Market by End User
    • 9.2.5. Europe RNAi Therapeutics Market by Country
  • 9.3. Asia-Pacific
    • 9.3.1. Asia-Pacific RNAi Therapeutics Market by Type
    • 9.3.2. Asia-Pacific RNAi Therapeutics Market by Application
    • 9.3.3. Asia-Pacific RNAi Therapeutics Market by Route of Administration
    • 9.3.4. Asia-Pacific RNAi Therapeutics Market by End User
    • 9.3.5. Asia-Pacific RNAi Therapeutics Market by Country
  • 9.4. RoW
    • 9.4.1. RoW RNAi Therapeutics Market by Type
    • 9.4.2. RoW RNAi Therapeutics Market by Application
    • 9.4.3. RoW RNAi Therapeutics Market by Route of Administration
    • 9.4.4. RoW RNAi Therapeutics Market by End User
    • 9.4.5. RoW RNAi Therapeutics Market by Sub-region

10. Company Profiles and Competitive Landscape

  • 10.1. Competitive Landscape in the Global RNAi Therapeutics Market
  • 10.2. Companies Profiles
    • 10.2.1. Alnylam Pharmaceuticals, Inc.
    • 10.2.2. Sanofi
    • 10.2.3. Olix Pharmaceuticals, Inc.
    • 10.2.4. Arbutus Biopharma Corporation
    • 10.2.5. Silence Therapeutics
    • 10.2.6. Rexahn Pharmaceuticals, Inc.
    • 10.2.7. Arrowhead Pharmaceuticals, Inc.
    • 10.2.8. Quark
    • 10.2.9. Others